Schedule of Events (Subject to change)

Date and Time Activity

Thursday September 19th Arrival

1500 – 2000 Registration

1430 – 1500 ISSTD Nominating Committee Meeting

1500 – 1730 ISSTD Executive Committee Meeting

1730 – 2000 ISSTD Reception

1830 – 1835 John Lurain, MD and Michael Seckl, MD - Welcome & Introduction

1835 – 1855 Kenneth Bagshawe, MD - The UK Perspective on the History of GTD

1855 – 1915 Charles Hammond, MD- The NCI Experience in the Treatment of GTN

1915 – 1930 Tigi Martin Dixon & Kerri Herman - Patient Experiences

Evening Events Dinner on own

Friday September 20th State of the Art: Gestational Trophoblastic Disease

0730 – 1700 Registration

0730 – 0800 Continental Breakfast

0800 – 0810 Welcome and Introduction – Emily Berry, MD

0810 – 0920 Session I: The Foundation of GTN

0810 – 0830 Donald Goldstein, MD, Personal Perspective on the History of GTD

0830 – 0850 Michael Wells, MD, Pathology of GTD

0850 – 0910 Rosemary Fisher, MD, Genetics of GTD

0910 – 0920 Moderator: LC Wong, MD - Questions

0920 – 1030 Session II: Molar Pregnancy

0920 – 0940 Ross Berkowitz, MD, Clinical Features of Complete and Partial Moles

0940 – 1000 John Tidy, MD, Surgical Management of Hydatidiform Moles

1000 – 1020 Fay Cagayan, MD, Complications of Molar Pregnancies

1020 – 1030 Moderator: Rafael Cortes-Charry, MD - Questions

1030 – 1100 Morning Break

1100 – 1230 Session III: Staging and Definition of Postmolar GTN

1100 – 1120 Ernest Kohorn, MD, FIGO Staging of GTD

1120 – 1140 Leon Massuger, PhD, Diagnosis of Postmolar GTN: FIGO Definitions versus use of hCG Regression Curves

1140 – 1200 Emily Berry, MD, Management of Low-level hCG’s

1200 – 1230 Moderator: PK Sekharan, MD - Panel Discussion, Decision-making regarding hCG plateaus/low values

1230 – 1330 Lunch

1330 – 1500 Session IV: Low-Risk GTN

1330 – 1345 Ray Osborne, MD, Overview of Treatment of Low-Risk GTN

1345 – 1400 Barry Hancock, MD, The UK Experience with MTX-FA for Treatment of Low-Risk GTN

1400 – 1415 Francois Golfier, MD, PhD, Changing Treatment in Low-Risk GTN

1415 – 1430 Julian Schink, MD, GOG 0275

1430 – 1500 Moderator: Vilmos Fulop, MD, PhD, DSc – Case-based Discussions

1500 – 1530 Afternoon Break

1530 – 1730 Session V: High-Risk GTN

1530 – 1545 Robert Coleman, MD, Initial Chemotherapy for High-Risk GTN

1545 – 1600 John Lurain, MD, Salvage Therapy for High-Risk GTN

1600 – 1615 Nikki Neubauer, MD, Brain Metastases in GTN

1615 – 1630 Michael Seckl, MD, Treatment of Ultra-High-Risk GTN

1630 – 1645 Hextan Ngan, MD, PSTT/ETT

1645 – 1700 Philip Savage, PhD, Follow Up and Side Effects After Treatment of GTN

1700 – 1730 Moderator: David Baartz, MD – Case-Based Discussions

1830 – 2200 Faculty Dinner

Evening events Dinner on own

Saturday September 21st

0730 – 1700 Registration

0730 – 0800 Breakfast

0800 – 0915 Plenary Session I: Experiences at GTN Referral Centers & Trophoblast Disease Registries

0800 – 0810 Introduction and Welcome

0810 – 0820 Epidemiological profile of patients with gestational trophoblastic disease (GTD) in a reference center in southern Brazil* Ellen Machado Arlindo, MD; Elza Maria Hartmann Uberti, PhD; Maria do Carmo Fajardo,MD; Adriana Gerhardt Vieira da Cunha, MD; Mirela Foresti Jimenez, PhD

0820 – 0830 Epidemiological report on the treatment of patients with gestational trophoblastic disease from 2000 to 2011 in Brazilian reference centers EH. Uberti and MC. Fajardo, Mario Totta Maternity of Irmandade da Santa Casa de Misericórdia de Porto Alegre, RS; A. Braga and P. Belfort (in memoriam), 33rd Maternity of Santa Casa da Misericórdia do Rio de Janeiro, RJ; MG. Viggiano et al., Hospital das Clínicas of the School of Medicine of UFGO, Goiânia, GO; S. Sun et al., Hospital São Paulo of Universidade Federal de São Paulo, São Paulo, SP; A. Braga et al., Hospital Universitário Antonio Pedro of UFF, Niterói, RJ; M. Martins et al., Hospital Universitário of UFMA, São Luis, MA; BM. Grillo and SL. Padilha, Hospital de Clínicas of UFPR, Curitiba, PR; JM. Andrade et al., Hospital de Clínicas da USP, Ribeirão Preto, SP; JM. Madi et al., Hospital Geral of UCS, Caxias do Sul, RS; I. Maestá et al., Hospital das Clínicas da Universidade Estadual Paulista, Botucatu, SP; E. Silveira et al., Hospital Guilherme Álvaro, Santos, SP.

0830 – 0840 Trends in the chemotherapeutic management of gestational trophoblastic neoplasia in the Philippines Cagayan, Maria Stephanie Fay S and Arellano, Divina Gracia L Section of Trophoblastic Disease, Department of Obstetrics and Gynecology, University of the Philippines-Philippine General Hospital, Taft Avenue, Manila

0840 – 0850 Quebec trophoblastic disease registry : A 4-year collaborative experience and Canadian perspectives Ph. Sauthier(1), M. Breguet(2), K. Rahimi(3), M. Martin(4), N. Letarte(5), R. Slim(6). (1)Gynecologic Oncology Division, (3)Pathology Department, (4)Biochemistry Department, (5)Pharmacy Department, Centre Hospitalier de l’Université de Montréal (CHUM), QC, Canada (2)Direction Québécoise de Cancérologie, Ministry of Health and Social Services, QC, Canada (6)McGill University Health Centre, Montreal, QC, Canada

0850 – 0911 Poster Review: Experiences at GTN Referral Centers Poster 1: Treatment of gestational trophoblastic neoplasia in the center of the trophoblastic diseases 33rd ward (maternity) Santa Casa da Misericordia do Rio de Janeiro F.Asmar, O.Vale,V. Moraes , P. Dantas, C. Novaes, J. Amim, J. Rezende,A. Braga SCMRJ, RJ,RJ Poster 2: Correlation between the clinical and histopathological forms with the symptomatology presented by patients accompanied the center of the trophoblastic diseases 33rd ward (maternity) Santa Casa da Misericórdia do Rio de Janeiro F. Asmar, SCMRJ, RJ, RJ Poster 3: Gestational trophoblastic neoplasia: A 16-year experience C Jacobs, K Chrystal, P Fong, B Evans. Department of Medical Oncology, Auckland District Health Board, Auckland, New Zealand. Poster 4: Queensland Trophoblast Centre (QTC) S.J. Morrison, Queensland Centre for Gynaecological Cancer (QCGC) Brisbane, QLD, Australia Gynaecologic Oncology, Royal Brisbane Women’s Hospital (RBWH) Brisbane, QLD, Australia M.J. Eddy, Queensland Centre for Gynaecological Cancer (QCGC) Brisbane, QLD, Australia Gynaecologic Oncology, Royal Brisbane Women’s Hospital (RBWH) Brisbane, QLD, Australia K.L. Sanday, Queensland Centre for Gynaecological Cancer (QCGC) Brisbane, QLD, Australia A.J. Garrett, Queensland Centre for Gynaecological Cancer (QCGC) Brisbane, QLD, Australia Gynaecologic Oncology, Royal Brisbane Women’s Hospital (RBWH) Brisbane, QLD, Australia Poster 5: Epidemiology in the referral center of gestational trophoblastic disease (GTD) at Antonio Pedro University Hospital – Fluminense Federal University (HUAP/UFF), Rio de Janeiro, Brazil Nicolle Guenther1, Adriene Ferreira1, Daniela Monteiro1, Luciano Marcolino1, Valéria Moraes1, Consuelo Lozoya1, Flávio Vasques1, Antonio Braga 1,2 1. Antonio Pedro University Hospital – Fluminene Federal University, Rio de Janeiro – Brazil 2. Santa Casa da Misericórdia do Rio de Janeiro, Brazil Poster 6: Gestational trophoblastic disease: Clinical trends in 12 years at a Venezuelan referral center R. Cortés-Charry, A. Salazar, L. Rodríguez, L. Ruíz Poster 7: A multicenter analysis of gestational trophoblastic neoplasia in Turkey S.Sinan Ozalp, Elcin Telli, Tufan Oge, Gokhan Tulunay, Nurettin Boran, Taner Turan, Kunter Yuce, Volkan Ulker, Muzaffer Sanci, Mehmet Gokcu, Gokhan Tosun, Yılmaz Dikmen, Aydin Ozsaran, Mustafa Cosan Terek, Levent Akman, Hakan Yetimalar, Tayfun Gungor, Emre Ozgu, Yunus Yıldız, Arif Kokcu, Mehmet Kefeli, Serkan Kuruoglu, Hasan Yuksel, Dagistan Tolga Arioz, Nadire Tuncer, Hasan Bozkaya, Suleyman Guven, Deniz Kulaksiz, Fusun Varol, Murat Api, Kadir Guzin, Eray Calıskan, Emek Doger, Bulent Cakmak S.S.Ozalp, E.Telli, T.Oge, M.D, Eskisehir Osmangazi University, School of Medicine, Department of Obstetrics and Gynecology, Eskisehir, Turkey G.Tulunay, N. Boran, T.Turan, M.D, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Department of Obstetrics and Gynecology, Ankara, Turkey K. Yuce, M.D, Hacettepe University, School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey V. Ulker, M.D, Kanuni Sultan Suleyman Teaching

and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey. M.Sanci,M.Gokcu,G.Tosun, M.D, Ege Gynecology and Maternity Training and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey Y. Dikmen, A. Ozsaran, M. C. Terek, L. Akman, M.D, Ege University, School of Medicine, Department of Obstetrics and Gynecology, Izmir, Turkey H. Yetimalar, M.D, Izmir Ataturk Training and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey T. Gungor, E. Ozgu, Y. Yıldız, M.D, Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Obstetrics and Gynecology, Ankara, Turkey. A. Kokcu, M. Kefeli, S. Kuruoglu, M.D, Ondokuz Mayis University, School of Medicine, Department of Obstetrics and Gynecology, Samsun, Turkey H.Yuksel, M.D, Adnan Menderes University, School of Medicine, , Department of Obstetrics and Gynecology, Aydin, Turkey D.T. Arioz, N. Tuncer, M.D, Afyon Kocatepe University, School of Medicine, Department of Obstetrics and Gynecology, Afyonkarahisar, Turkey H. Bozkaya, S. Guven, D. Kulaksiz, M.D, Karadeniz Technical University, School of Medicine, Department of Obstetrics and Gynecology, Trabzon, Turkey F.Varol, M.D, Trakya University, School of Medicine, Department of Obstetrics and Gynecology, Edirne, Turkey M.Api, M.D, Zeynep Kamil Maternity and Pediatric Research and Training Hospital, , Department of Obstetrics and Gynecology, Istanbul, Turkey K.Guzin, M.D, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Department of Obstetrics and Gynecology, Istanbul, Turkey E.Caliskan, E. Doger M.D, Kocaeli University, School of Medicine, Department of Obstetrics and Gynecology, Kocaeli, Turkey B.Cakmak, M.D, Gaziosmanpasa University, School of Medicine, Department of Obstetrics and Gynecology, Tokat,Turkey

0911 – 0915 Q & A

0915 – 1000 Break and View Posters (Dedicated Poster Presentation Time)

1000 – 1215 Plenary Session II: Genetics and Molecular Pathways

1000 – 1005 Introduction

1005 – 1015 Hydatidiform moles and tetraploidy Lone Sunde, Linda Sundvall, Isa Niemann, Helle Lund, Uffe Birk Jensen, Lars Bolund Dept. of Biomedicine, Aarhus University; Dept. of Clinical Genetics and Dept. of Gynecology and Obstetrics, Aarhus University Hospital; Inst. of Pathology, Aalborg University Hospital; Denmark

1015 – 1025 NLRP7 or KHDC3L are not common causes of mosaic moles, non-familial biparental moles, hydatidiform mole plus recurrent miscarriages, familial androgenetic, or recurrent androgenetic hydatidiform moles L. Andreasen1,2,3*, O.B. Christiansen4,5, I. Niemann6, L. Bolund2,3 and L. Sunde1,2 1Department of Clinical Genetics, Aarhus University Hospital, Skejby, Aarhus N-8200, Denmark; 2Department of Biomedicine, Aarhus University, Aarhus-8000, Denmark; 3BGI-Shenzhen HuaDa JiYin, Shenzhen, China; 4The Fertility Clinic, University Hospital Copenhagen, Rigshospitalet, Copenhagen-2100, Denmark; 5Department of Obstetrics and Gynaecology, Aalborg Hospital, Aalborg University Hospital, Aalborg-9100, Denmark; 6Department of Gynaecology and Obstetrics, Aarhus University Hospital, Skejby, Aarhus N-8200, Denmark.

1025 – 1035 Risk of recurrent hydatidiform mole after complete or partial molar pregnancy Rosemary A Fisher, Neil J Sebire, Natasha Eagles, Dee Short, Philip M Savage, Michael J Seckl

1035 – 1045 The gene expression of HIF-1α mRNA in the pathogenesis of The progression of complete hydatidiform mole to gestational trophoblastic neoplasia RI Perbawati, AB Harsono, H Susanto Department of Obstetric and Gynecology, Padjadjaran University School of Medicine, Hasan Sadikin Hospital, Bandung, Indonesia

1045 – 1055 Analysis of Syncytin-1 protein interaction network in gestational trophoblastic disease malignant transformation P-A. Bolze Department of Obstetrics and Gynecology, Lyon 1 University, Lyon

Hospital, Lyon Sud University Hospital, Lyon, French Trophoblastic Disease Reference Centre, 69495 Pierre-Bénite Cedex France F. Mallet Laboratoire Commun de Recherche Hospices Civils de Lyon – bioMérieux, Cancer Biomarkers Research Group, Lyon Sud University Hospital, 69495 Pierre-Bénite Cedex, France S. Patrier Department of Pathology, Rouen University Hospital, 76031 Rouen, French Trophoblastic Disease Reference Centre, France F. Golfier Department of Obstetrics and Gynecology, Lyon 1 University, Lyon Hospital, Lyon Sud University Hospital, Lyon, French Trophoblastic Disease Reference Centre, 69495 Pierre-Bénite Cedex France

1055 – 1105 Endoglin as a potential target for the treatment of gestational trophoblastic neoplasia KM Elias, KT Hasselblatt, SW Ng, RS Berkowitz, and NS Horowitz. New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

1105 – 1115 The effect of ethinyl estradiol and desogestrel on proliferation and apoptosis in hydatidiform mole trophoblast cell Andrijono, Division Gynecology Oncology Indonesia University, Jakarta Indonesia Wan Lelly H and Sri Hartini, Dharmais Cancer Center Hospital, Jakarta Indonesia Bambang Sutrisna, Community Medicine Faculty University of Indonesia, Depok Indonesia

1115 – 1125 p-21-activated kinase-1, -4 and -6 and estrogen receptor expression pattern in normal placenta and gestational trophoblastic diseases M. Shoni, MD¹, Z. Nagymanyoki, MD, PhD², A. Vitonis¹, J. Cynthia, MD², SW. Ng, PhD¹, B. Quade, MD, PhD², R. Berkowitz, MD¹³ ¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ² Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA ³ Donald P Goldstein, MD, Trophoblastic Tumor Registry, New England Trophoblastic Disease Center, MA, USA

1125 – 1135 Type I interferon signaling controls methotrexate resistance in choriocarcinoma KM Elias, KT Hasselblatt, M Sclanders, SW Ng, OE Pardo, MJ Seckl, and RS Berkowitz New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Lung Cancer Biology Group, Imperial College London, London, UK; Trophoblastic Disease Centre, Imperial College London, London, UK

1135 – 1145 Absence of KHDC3L mutations in Chinese patients with recurrent and sporadic hydatidiform moles JianHua Qian,Hangzhou First People’s Hospital, Hangzhou hospital of Nanjing Medical University, Hangzhou 310006, China. Wei Zhao.Women’s Reproductive Health Laboratory, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Cheng Qi.Women’s Reproductive Health Laboratory, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Rima Slim.Departments of Human Genetics and dObstetrics and Gynecology, McGill University Health Centre, Montreal H3G 1A4, Canada.

1145 – 1155 Choriocarcinoma genomic alterations associated with clinical outcome J. B. H. Mello, I. Maestá, A. C. T. Tavares, M. A. C. Domingues, M. V. C. Rudge, S. R. Rogatto Neogene Laboratory of Department of Urology, Trophoblastic Diseases Center of the Department of Gynecology and Obstetrics, and Department of Pathology, Botucatu Medical School, São Paulo State University/UNESP, Botucatu,

São Paulo, Brazil

1155 – 1205 NLRP7, a NOD-like receptor protein, is required for normal cytokine secretion and co-localizes with the Golgi and the microtubule organizing center Rima Slim, Christiane Messaed, Elie Akoury, Ugljesa Djuric, Jibin Zeng, Muhhiedine Seoud

1205 – 1215 Q&A

1215 – 1315 Lunch

1315 – 1445 Plenary Session III: Molar Pregnancy

1315 – 1320 Introduction

1320 – 1330 The clinical epidemiology and management of hydatidiform mole at the Santa Casa da Misericórdia do Rio de Janeiro Reference Center in Brazil – 54-years of experience Jorge Rezende-Filho1,3; Osvaldo Vale1, Daniel Munene1, Valéria Moraes1,2, Carlos Eduardo Novaes1, Joffre Amin-Júnior1,3, Antonio Braga1,2 1 Santa Casa da Misericórdia do Rio de Janeiro, 2 Fluminense Federal University – Antonio Pedro University Hospital, 3 Rio de Janeiro Federal University

1330 – 1340 Hydatidiform mole clinical characteristics and outcomes in adolescents: a study in South American centers R. R. Soares, I. Maestá, J. Colón, A. Braga, A. Salazar, R. C. Charry Trophoblastic Disease Center, Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP- São Paulo State University, Botucatu,SP, Brazil; Maternidad Concepción Palácios de Caracas, Venezuela; Trophoblastic Disease Center, University Hospital Antonio Pedro, Fluminense Federal University, Niterói, Brazil; Department of Obstetrics and Gynecology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela.

1340 – 1350 Incidence of hydatidiform mole in Denmark 1999 – 2010 H. Lund, A. Grove, M. Vyberg, L. Sunde. Institute of Pathology, Aalborg University Hospital, Aalborg; Dept. of Clinical Genetics, Aarhus University Hospital & Institute of Biomedicine, Health, Aarhus University; Denmark

1350 – 1400 Influence of race on type and severity of hydatidiform mole Laura Felder, BA,MS1, Michael Worley MD1, Shu-Kay Ng2, PhD, Shu-Wing Ng, PhD1, Donald P. Goldstein, MD1, Ross S. Berkowitz, MD1, Neil S. Horowitz, MD1. 1Department of Obstetrics and Gynecology, New England Trophoblastic Disease Center, Brigham and Women's Hospital, Boston, MA. 2 Griffith Health Institute, Griffith University, Meadowbrook QLD 4131, Australia

1400 – 1410 Clinical usefulness of immunohistochemical staining of p57kip2 for differential diagnosis of complete mole S. Sasaki*, Y. Sasaki**, A.Sekizawa**, T. Kunimura***, Y. Kojima****, K. Iino* * Dept of Ob-Gyn, Iino Hospital, Chofu, Tokyo, ** Dept of Ob-Gyn, ***Division of Pathology, Showa University School of Medicine, Yokohama & Tokyo **** Kojima Maternity Clinic, Akishima, Tokyo

1410 – 1420 Short repeat tandem assay refines the diagnosis of hydatidiform moles S.Patrier (1), F.Marguet (1), A.Lamy (1), M.Crahes (1), JC.Sabourin (1), PA.Bolze (2) and F.Golfier (2) (1) Department of Pathology, Universitary Hospital,Rouen, France (2) French Center for Trophoblastic Diseases, Hospices Civils, Lyon, France

1420 – 1430 CGH+SNP microarray analysis of complete and partial hydatidiform moles U Surti and L Hoffner Magee Womens Hospital and Magee Womens Research Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

1430 – 1440 p57 kip2 immunohistochemistry: Ancillary technique in hydatidiform mole diagnosis R Cortés-Charry, J Fernández, V García, P Dabed, A Salazar, A Pulido

1440 – 1445 Q&A

1445 – 1515 Break and View Posters (Dedicated Poster Presentation Time)

1515 – 1640 Plenary Session IV: Clinical Features, Risk Factors & Complications of Hydatidiform Moles

1515 – 1520 Introduction

1520 – 1530 Hydatidiform mole clinical characteristics, initial treatment and outcomes in women of advanced age: A study in South American centers C.C.F. Desmarais, I. Maesta, J. Colón, A. Braga, M.I. Bianconi, G. Jankilevich, A. Salazar, R.C. Charry Trophoblastic Disease Center, Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP- São Paulo State University, Botucatu,SP, Brazil; Maternidad Concepción Palácios de Caracas, Venezuela; Trophoblastic Disease Center, University Hospital Antonio Pedro, Fluminense Federal University, Niterói, Brazil;Durand Hospital Trophoblastic Disease Center, Hospital Carlos G Durand, Buenos Aires, Argentina; Department of Obstetrics and Gynecology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela.

1530 – 1540 Current clinical features of complete and partial hydatidiform mole in Sweden U. Joneborg and L. Marions, Dpt of Ob/Gyn, Karolinska University Hospital, Stockholm, Sweden

1540 – 1550 Women with a partial mole during their first pregnancy and diagnosed earlier in gestation are at increased risk of developing gestational trophoblastic neoplasia MJ. Worley, Jr., (1,2,3,4), NT. Joseph, (5), RS. Berkowitz, (1,2,3,4) and DP. Goldstein (1,2,3,4) (1) Division of Gynecologic Oncology, Brigham and Women’s Hospital, Boston, USA. (2) New England Trophoblastic Disease Center, Donald P. Goldstein, M.D., Trophoblastic Tumor Registry, Boston, USA. (3) Dana Farber Cancer Institute/Harvard Cancer Center, Boston, USA. (4) Harvard Medical School, Boston, USA. (5) Brigham and Women’s Hospital/Massachusetts General Hospital Integrated Residency Program in Obstetrics and Gynecology, Boston, USA

1550 – 1600 Histopathological and immunohistochemical features of early hydatidiform moles in relation to subsequent development of persistent gestational trophoblastic disease NJ Sebire, G Petts, R Fisher, D Short, I Lindsay, MJ Seckl Charing Cross Trophoblastic Disease Unit, London, UK

1600 – 1610 Malignancy risk factors of hydatidiform moles Heru Pradjatmo, Djaswadi Dasuki, Suroso Obgyn Department, Faculty of Medcine, GMU/Sardjito Hospital

1610 – 1620 Modern hormonal contraceptive use before hCG remission does not increase the risk of persistent trophblastic disease (PTD) following complete hydatidiform mole (CHM) Antonio Braga1.2, Dee Short3, Maestá Izildinha1,2, Philip Savage3, Richard Harvey3, Michael J Seckl3. 1Trophoblastic Disease Center, Antonio Pedro University Hospital at Fluminense Federal University, Niteroi, Brazil; 2Trophoblastic Disease Center, Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP - São Paulo State University, Botucatu,SP, Brazil; 3Charing Cross Gestational Trophoblastic Disease Centre, Imperial College London, UK

1620 – 1630 Frequency of persistent gestational trophoblastic disease (PTD) after spontaneous normalisation of hCG following a hydatidiform molar (HM) pregnancy. C. Coyle, D. Short, L. Dayal, L. Horsley, N.J. Sebire, B. Kaur, R. Harvey, P.M. Savage and M.J. Seckl Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital campus of Imperial College London, UK.

1630 – 1636 Poster Review on Complications of Molar Pregnancy Poster 8: A successful outcome of a molar pregnancy complicated by potentially life-threatening hyperthyroidism and ovarian hyperstimulation syndrome J. Coulter, M O' Riordan and P. Kelly, Cork University Maternity Hospital, Ireland Poster 9: Subclinical hyperthyroidism in a population with molar pregnancy R. Cortés-Charry, A. Salazar, A. Maldonado, H. Rodríguez, G. Montero, A. Borges. Trophoblastic Clinic of the Department of Obstetrics and Gynecology. Hospital Universitario de Caracas. Universidad Central de Venezuela. Caracas. Distrito Capital

1636 – 1640 Q&A

1700 – 1900 European Organisation for Treatment of Trophoblastic Diseases Meeting

Evening Events Evening on own

Sunday September 22nd

0700 – 1700 Registration

0700 – 0730 Breakfast

0730 – 0915 Plenary Session V: Twin Moles & hCG

0730 – 0740 Introduction

0740 – 0750 Hydatidiform mole with a live fetus - A series of 26 patients Antonio Braga1,2, Joffre Amim Júnior3, Jorge Rezende-Filho1,3, Izidinha Maestá4, Anice Maria Vieira de Camargo Martins4, Sue Sun5, Renato Souza5, Aleydah Salazar6, Rafael Cortés-Charry6 Santa Casa da Misericórdia do Rio de Janeiro, Brazil; 2. Antonio Pedro University Hospital, Brazil; 3. Rio de Janeiro Federal University, Brazil; 4. Trophoblastic Diseases Center of the Department of Gynecology and Obstetrics, Botucatu Medical School, São Paulo State University, Brazil; 5. São Paulo Federal University, Brazil; 6. Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela

0750 – 0800 Update on UK outcomes for women with twin pregnancies comprising a complete hydatidiform mole (CHM) and normal co-twin I Niemann, R Fisher, N Sebire, M Wells, D Short, J Tidy, B Hancock, R E Coleman, P M Savage, and M J Seckl Combined Charing Cross and Weston Park Gestational Trophoblastic Disease Centres, UK

0800 – 0810 Human chorionic gonadotropin regression in non molar pregnancy. Preliminary study R Cortés-Charry, N Corredor, N García, J Fernández, A Salazar, M Fargioni. Trophoblastic Clinic of the Department of Obstetrics and Gynecology. Hospital Universitario de Caracas. Universidad Central de Venezuela. Caracas, Venezuela.

0810 – 0820 Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia I. Maestá, W.B. Growdon, D.P. Goldstein, M. R. Bernstein, N.S. Horowitz, M. V. C. Rudge, R. S. Berkowitz Trophoblastic Disease Center, Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP- São Paulo State University, Botucatu,SP, Brazil; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Cancer Center/Dana-Faber Cancer Institute; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital; New England Trophoblastic Disease Center, Donald P. Goldstein, M.D., Trophoblastic Tumor Registry, and Harvard medical School, Boston, Massachusetts.

0820 – 0830 Utility of serum human chorionic gonadotrophin free β-subunit (hCGβ) measurement in the management of gestational trophoblastic neoplasia (GTN) R A Harvey, P Wardell, R Caser-Lahoy, N Sebire, D Short, P M Savage, M J Seckl.

Charing Cross Hospital Trophoblastic Disease Centre, London, UK

0830 – 0840 Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type J. Massardier, C. Schmitt, P.A. Bolze, T. Hajri, A.M. Schott, B.You, S Patrier, M. Doret, D. Raudrant, F. Golfier. French Trophoblastic Disease Center, Hospices Civils de Lyon, Université de Lyon, France

0840 – 0850 Time to hCG normalisation in patients with hydatidiform molar pregnancy (HM) and risk of persistent gestational trophoblastic disease (PTD) C. Coyle, D. Short, L. Dayal, L.Horsley, N.J. Sebire, B. Kaur, R.Harvey, P. M. Savage and M. J Seckl

0850 – 0900 Comparative analysis of hCG kinetic profiles in a large international pooled cohort of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with 3 different treatment regimens Benoit You; Olivier Colomban; Richard Harvey; Michael J Seckl; Raymond Osborne; François Golfier

0900 – 0915 Q&A

0915 – 0945 Break and Visit Posters

0945 – 1205 Plenary Session VI: Low-risk GTN

0945 – 0950 Introduction

0950 – 1000 Actinomycin D for the treatment of low risk gestational trophoblastic neoplasia in Brisbane, Queensland – a change in institution policy A. Garrett, K. Sanday, S. Morrison, D. Baartz, J. Eddy Queensland Trophoblast Centre, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia

1000 – 1010 Peroral methotrexate as initial treatment for postmolar Gestational Trophoblastic Neoplasia regardless of risk group – a 30-year experience at Aarhus University Hospital, Denmark L. Faaborg, JC. Lindegaard and I. Niemann Department of Oncology and Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark

1010 – 1020 Which chemotherapy regimen do women prefer for low-risk GTN: a survey and derivation of utility values C.J. Reade (1), L.R. Eiriksson (1), R. Osborne (2), N.T. Shah (3), J. Dodge(4), F. Moens (5), R. Goeree (6) Institutions: (1) Division of Gynecologic Oncology, University of Toronto, Toronto, Canada, (2) Odette Cancer Center, Sunnybrook Health Sciences, Toronto, Canada, (3) Brigham & Women's Hospital, Boston, MA, (4)Princess Margaret Hospital, Toronto, Canada, (5) Juravinski Cancer Centre, Hamilton, Canada, (6) PATH Research Institute, McMaster University, Hamilton, Canada

1020 – 1030 Chemotherapy for low-risk GTN: a probabilistic decision analysis model C.J. Reade (1), R. Osborne (2), N. Shah (3), L.R. Eiriksson (1), J. Dodge(4), F. Moens (5), R. Goeree (6) Institutions: (1) Division of Gynecologic Oncology, University of Toronto, Toronto, Canada, (2) Odette Cancer Center, Sunnybrook Health Sciences, Toronto, Canada, (3) Brigham & Women's Hospital, Boston, MA, (4)Princess Margaret Hospital, Toronto, Canada, (5) Juravinski Cancer Centre, Hamilton, Canada, (6) PATH Research Institute, McMaster University, Hamilton, Canada

1030 – 1040 Treatment of low-risk gestational trophoblastic neoplasia (GTN) – A single institution and original cohort study comparing two single-agent chemotherapy regimens: Biweekly use of eight-day high-dose methotrexate plus folinic acid rescue and pulsed actinomycin-D Elza Maria Hartmann Uberti, PhD; Maria do Carmo Fajardo, MD: Adriana Gerhardt Vieira da Cunha, MD; Silvia Villa Verde Ribeiro Ferreira, Psychologist ; Sirlene Soares Frota, Oncological Nurse; Antonio Celso Koehler Ayub, MD.

1040 – 1050 Low-risk gestational trophoblastic neoplasia (GTN) first attempt resistant to

treatment: Is polychemotherapy needed? Otero S.; Bianconi M.,Alvarez L Storino C Jankilevich G, Servicio de Oncología; Hospital Carlos G. Durand ,GCBA

1050 – 1100 Single-agent carboplatin as second-line therapy for methotrexate-resistant gestational trophoblastic neoplasia R Coleman, J Cook, A Hills, S Gillett, J Tidy, M Winter. Sheffield Trophoblastic Centre, Weston Park Hospital, Sheffield, UK

1100 – 1110 Etoposide and dactinomycin as second-line low-risk treatment for gestational trophoblastic neoplasia: A decade of experience at the Sheffield Centre for Trophoblastic Disease, United Kingdom M.C. Winter, J.E. Everard, F.A. Khan, J. A. Tidy, B.W. Hancock, R.E. Coleman Sheffield Centre for Trophoblastic Disease, Weston Park Hospital, Sheffield, United Kingdom

1110 – 1120 How to treat patients with low-risk GTN FIGO score 5-6 Toshiyuki Kanno1), Hideo Matsui1), Maki Kihara1), Hirokazu Usui2), Makio Shozu2) 1) Department of Obstetrics & Gynecology, Tokyo Women’s medical University, 8-1 Kawada-cho, Shinnjuku-ku, Tokyo, 162-8666, Japan 2) Department of Reproductive Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

1120 – 1130 A review of the management and outcomes of patients with low-risk GTN treated in Sheffield, UK from 1997 to 2006 M C Macdonald, Sheffield Teaching Hospitals, Jessop Hospital WIng, Sheffield, UK B W Hancock, Sheffield Teaching Hospitals, Weston Park Hospital, Sheffield, UK M C Winter, Sheffield Teaching Hospitals, Weston Park Hospital, Sheffield, UK R E Coleman, Sheffield Teaching Hospitals, Weston Park Hospital, Sheffield, UK J A Tidy,Sheffield Teaching Hospitals, Royal Hallamshire Hospital, Sheffield, UK

1130 – 1140 Barriers and solutions to activating an international phase III randomized trial of low-risk gestational trophoblastic neoplasia (GTN): The GOG 275 experience J.C. Schink, Northwestern University, Chicago, IL J. Tidy, Sheffield Teaching Hospitals, Sheffield, UK M. Seckl, Charing Cross GTD Center, London, UK R. J. Osborne, Toronto-Sunnybrook Regional Cancer Center, Toronto, CA J. Carter, Memorial Sloan Kettering Cancer Center, New York, NY V. Filiaci, GOG Statistical & Data Center at Roswell Park Cancer Institute, Buffalo, NY H. Huang, GOG Statistical & Data Center at Roswell Park Cancer Institute, Buffalo, NY D.S. Miller, UT Southwestern Medical Center, Dallas, TX

1140 – 1150 Patients treated for low-risk GTN in Sheffield, UK from 1997 to 2006: A comparison of management and outcomes of patients with Stage I and Stage III disease M C Macdonald, Jessop Hospital Wing, Sheffield Teaching Hospitals, Sheffield, UK B W Hancock, Weston Park Hospital, Sheffield Teaching Hospitals, Sheffield, UK M C Winter, Weston Park Hospital, Sheffield Teaching Hospitals, Sheffield, UK R E Coleman, Weston Park Hospital, Sheffield Teaching Hospitals, Sheffield, UK J A Tidy, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK

1150 – 1200 The utility of uterine pulsatility index (UAPI), hCG isoforms and angiogenic factors in predicting methotrexate (MTX) resistance in low-risk gestational trophoblastic neoplasia (GTN) R A Harvey, M Papadaki, R A Fisher, N J Sebire, D Short, P M Savage, *U H Stenman, *T Grӧnholm, R Agarwal and M J Seckl. Charing Cross Hospital Trophoblastic Disease Centre, London, UK. *Dept of Clinical Chemistry, Helsinki University Central Hospital, Finland.

1200 – 1205 Q&A

1205 – 1300 Lunch

1300 – 1420 Plenary Session VII: Reproductive Outcomes

1300 – 1305 Introduction

1305 – 1315 Anti-mullerian hormone (AMH) levels in patients treated with chemotherapy for gestational trophoblastic neoplasia (GTN): Is it a reliable assessment of fertility following treatment? R. Ramaswami, P.M.Savage, M.J. Seckl Charing Cross Gestational Trophoblastic Disease Centre, Imperial College NHS Healthcare Trust, London UK

1315 – 1325 Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia J.M.K. Wong, D. Liu, J.C. Schink, J.R. Lurain. Northwestern University, Feinberg School of Medicine, Chicago, IL.

1325 – 1335 Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia: Updated results R. Vargas 1, L. Diver 1, L. Barroilhet 2, K. Esselen 1, L. Garrett 3, M. Bernstein 1, D. Goldstein 1, R. Berkowitz 1. 1. Brigham & Women's Hospital, Boston, MA 2. University of Wisconsin Hospital and Clinics, Madison, WI 3. Beth Israel Deaconess Hospital, Boston, MA

1335 – 1345 The effects of chemotherapy treatment for gestational trophoblastic tumours on second tumour risk and early menopause PM Savage, R Cook, J O’Nions, J Krell, A Kwan, M Camarata, G Dancy, D Short, A Swerdlow, MJ Seckl. Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital campus of Imperial College London, UK. Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK

1345 – 1355 The impact of body mass index (BMI) on the clinical presentation and outcomes of women with gestational trophoblastic neoplasia (GTN) Janelle Moulder, MD, Allison F. Vitonis, SM, Ross Berkowitz MD, Donald P. Goldstein, MD. Marilyn R. Bernstein, and Neil S. Horowitz, MD

1355 – 1405 The effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia (GTN) Jennet Williams, Dee Short, Linda Dayal, Sarah Strickland, Richard Harvey, Terry Tin, Philip M Savage and Michael J Seckl Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital campus of Imperial College London, UK.

1405 – 1415 Recommendations of the European Organisation for Treatment of Trophoblastic Diseases about management of gestational trophoblastic diseases P-A. Bolze, Department of Obstetrics and Gynecology, Lyon 1 University, Lyon Hospital, Lyon Sud University Hospital, Lyon, French Trophoblastic Disease Reference Centre, France J. Attia, Department of Obstetrics and Gynecology, Lyon 1 University, Lyon Hospital, Lyon Sud University Hospital, Lyon, French Trophoblastic Disease Reference Centre, France J. Massardier, Department of Obstetrics, Hôpital Femme – Mère – Enfant, Lyon Hospital, Lyon, French Trophoblastic Disease Reference Centre, France M. Seckl, London, United Kingdom, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, London W68RF, United Kingdom L. Massuger, Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands N. van Trommel, Fellow gynecologic oncology, centre for gynecologic oncology Amsterdam, academical medical centre Amsterdam, The Netherlands T. Hajri, Department of Obstetrics and Gynecology, Lyon 1 University, Lyon Hospital, Lyon Sud University Hospital, Lyon, French Trophoblastic Disease Reference Centre, France A-M. Schott, French Trophoblastic Disease Reference Centre, Lyon Sud University Hospital, Lyon, France, Lyon 1 University, Pôle IMER, Lyon, France F. Golfier for the EOTTD group Department of Obstetrics and Gynecology, Lyon 1 University, Lyon Hospital, Lyon Sud University Hospital, Lyon, French Trophoblastic Disease Reference Centre, France

1415 – 1420 Q&A

1420 – 1450 Break and View Posters

1450 – 1540 Plenary Session VIII: Chemotherapy for High-risk GTN

1450 – 1455 Introduction

1455 – 1505 Role of capecitabine in the management of gestational trophoblastic neoplasia (GTN): A drug for two settings MI Bianconi.1, S Otero 1, CS torino 2,, G Jankilevich.1 1Clinical Oncology Service, Hospital Carlos Durand, Buenos Aires, Argentina 2Obstetrics and Gynecology Unit, Hospital Carlos Durand, Buenos Aires, Argentina

1505 – 1515 Changes in the management of high-risk GTN in the National Trophoblastic Disease Center of Hungary Vilmos Fülöp, M.D1., Iván Szigetvári, M.D1., János Szepesi, M.D2., György Végh, M.D2, and Ross S. Berkowitz, M.D3. 1Department of OB/GYN, State Health Center, Budapest, Hungary, 2Department of OB/GYN, Peterfy Hospital, Budapest, Hungary, 3Department of OB/GYN, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

1515 – 1525 The effectiveness of TP/TE & EMA-EP regimens as salvage chemotherapy in patients of refractory or recurrent gestational trophoblastic tumors SJ Kim, SG Jung, MC Choi, H Park, JM Lee, YY Hwang, C Lee

1525 – 1535 An update of TE/TP activity in EMA/CO failures and the plan for a TE/TP vs EP/EMA trial M J Seckl1, D Short1, J Warwick2, R Harvey1, N J Sebire1, B Kaur1, S Strickland1, J Reise2, P M Savage1 1 Charing Cross Hospital Trophoblastic Disease Centre, and 2 Imperial Clinical Trials Unit, Imperial College London LONDON, UK

1535 – 1540 Q&A

1730 – 2200 Boat Tour and Dinner

Monday September 23rd

0730 – 1200 Registration

0730 – 0800 Breakfast

0800 – 0930 Plenary Session IX: Metastatic Disease & Choriocarcinoma

0800 – 0805 Introduction

0805 – 0815 Brain metastases in gestational trophoblast tumors: An update on incidence, management and outcome PM Savage, I Kelpanides, M Tuthill, D Short and M J Seckl

0815 – 0825 Vaginal metastases in gestational trophoblastic disease: Low risk or not? Mireille Vree ,Department of Obstetrics and Gynaecology, Erasmus University Medical Centre Rotterdam, the Netherlands, MD; Christianne AR Lok, Department of Gynaecology, Centre of Gynaecologic Oncology Amsterdam, The Netherlands, MD, PhD; Leon FAG Massuger, Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, MD, PhD, Fred CGJ Sweep, Laboratory of endocrinology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. MD, PhD, Marianne J ten Kate-Booij, MD, PhD ,Department of Obstetrics and Gynaecology, Erasmus University Medical Centre Rotterdam, the Netherlands.

0825 – 0835 Pulmonary metastases: A negative influence on prognosis in gestational trophoblastic disease? M. Vree (a), N. van Trommel (b), L. Massuger (c), F. Sweep (d), G. Kenter (e), C. Thomas (d), C. Lok (e) (a) Department of Obstetrics and Gynaecology, VU University Medical Centre, Amsterdam, The Netherlands (b) Department of Obstetrics and Gynaecology, Catharina Hospital Eindhoven, The Netherlands, (c) Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Center,

Nijmegen, The Netherlands, (d) Department of Laboratory Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, (e) Department of Gynaecology, Centre of Gynaecologic Oncology Amsterdam, The Netherlands

0835 – 0845 Hepatic metastases in gestational trophoblastic neoplasia: Patient characteristics, prognostic factors and outcomes E.L. Barber; J.C. Schink; J.R. Lurain. Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chicago, IL 60611

0845 – 0855 Evaluating response to first-line treatment in term and non-term choriocarcinoma C. Milligan, R. Coleman, J. Tidy, B. Hancock Centre for Trophoblastic Disease, Sheffield UK

0855 – 0905 Changes in clinical presentation of postterm choriocarcinoma at the a regional referral center in recent years E. Diver, T. May, R. Vargas, M. Bernstein, D. Goldstein, R. Berkowitz. All of BWH Gyn Onc and NETDC, Boston, MA.

0905 – 0915 Fatal gestational choriocarcinoma: Analysis of treatment failures from 1979-2012 compared to 1962-1978 NL. Neubauer, M.D., A Strohl, M.D., JC Schink, M.D., JLurain, M.D. Department of Obstetrics and Gynecology, John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

0915 – 0927 Poster Review: ETT & Choriocarcinoma Poster 10: Positron emission tomography imaging in restaging recurrent epithelioid trophoblastic tumor E. Zsiros, University of Pennsylvania, Philadelphia, PA S. Jean, University of Pennsylvania, Philadelphia, PA S.C.Rubin, University of Pennsylvania, Philadelphia, PA Poster 11: Combined modality therapy of metastatic epithelioid trophoblastic tumor: a report of two cases E. Berry, MD, Northwestern University Feinberg School of Medicine, Prentice Women's Hospital, Chicago, IL USA A. V. Hoekstra, MD, West Michigan Cancer Center, Kalamazoo, MI USA J.R. Lurain, MD, Northwestern University Feinberg School of Medicine, Prentice Women's Hospital, Chicago, IL USA Poster 12: Choriocarcinoma diagnosis 22 years after spontaneous remission of a complete hydatidiform mole - A case report EH. Uberti,PhD; MC. Fajardo, MD; AG. Vieira da Cunha, MD: G. de Napoli, MD; JP.Furtado, MD; JJP. Camargo, MD.; Trophoblastic Disease Center of Irmandade da Santa Casa de Misericórdia de Porto Alegre, RS, Brazil. Poster 13: Partial hysterectomy as a treatment for patients with gestational choriocarcinoma and chemoresistance. About 2 cases from the French Trophoblastic Disease Center. J. Massardier, F. Couder, P.A. Bolze, B. You, V. Trillet-Lenoir, M. Devouassoux, M. Leheurteur, M.P. Quemere, T. Hajri, D. Raudrant, A.M. Schott, F. Golfier

0927 – 0930 Q&A

0930 – 1000 Break & View Posters

1000 – 1120 Plenary Session X: PSTT

1000 – 1005 Introduction

1005 – 1015 Prognostic markers of recurrence for patients with stage I placental site

trophoblastic tumor X. Yi and L. Bao, Department of Gynecology, Hospital of Obstetrics and Gynecology, Fudan University, Shanghai 200090, PR China.

1015 – 1025 PSTT – A diagnostic and therapeutic challenge U. Joneborg and L. Marions, Dpt of Ob/Gyn, Karolinska University Hospital, Stockholm, Sweden

1025 – 1035 Placental site trophoblastic tumor: Clinical presentation, pathology, treatment and prognosis J. Zhao, Y. Xiang, X.R. Wan, F.Z. Feng, T. Ren (1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.) L.N. Guo (2 Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.)

1035 – 1045 Placental site and epithelioid trophoblastic tumors: A series of 22 patients F Golfier, A Moutte, T Hajri, N Peyron, F Chateau, J Massardier, PA Bolze, P Duvillard, S Patrier, AM Schott, J Attia, B You, D Raudrant.

1045 – 1055 An innovative morphological MRI classification of placental site trophoblastic tumors F. Golfier, N. Peyron Faure, P. Rousset, F. Chateau, L. Frappart, F. Réty French Trophoblastic Disease Centre, Lyon, France Department of Gynecological and Oncological Surgery, Department of Radiology, Lyon Sud University Hospital, Lyon, France

1055 – 1105 Atypical placental site nodule (APSN): A clinicopathological study of 21 cases Baljeet Kaur, Dee Short, Michael J Seckl , Philip M Savage, Richard Harvey, Fisher Rosemary and Neil J Sebire. Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital campus of Imperial College London, UK.

1105 – 1115 The ISSTD global placental site and epithelioid trophoblastic tumour (PSTT/ETT) database – An analysis of the first 210 patients B. Hancock, A. Burnett, R. Berkowitz, D. Goldstein, F. Golfier, L. Massuger N. van Trommel, Y.Chen, Ph. Sauthier, R. Coleman, J. Tidy, P.Savage, L. Ellis, D. Short, S. Mori, J. Horsman, M. Bernstein, R. Smith,N. Sebire, M. Wells, M. Seckl Centres for Gestational Trophoblastic Disease Sheffield and London, UK, New England Trophoblastic Disease Center, Boston, US, Centre Français des Maladies Trophoblastiques, Lyon, Radboud University Nijmegen Medical Centre, The Netherlands, Zhejiang University, Hangzhou, China, Centre Hospitalier de l'Université de Montréal, Canada

1115 - 1120 Q&A

1120 – 1150 International Society for the Study of Trophoblastic Diseases General Assembly

1150 – 1155 Awards Presentation for Outstanding Oral and Poster Presentation

1155 – 1205 Concluding remarks

1210 Course concludes